In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aidan Fry

With over 20 years of experience of reporting on the global pharmaceutical industry, Aidan focuses in his role as editor of Generics bulletin particularly on commercial, regulatory and legal issues affecting the generic, biosimilar, value-added and OTC medicines industries. This includes in-depth analyses of corporate strategy, legislative changes, legal precedents and product perspectives. He regularly interviews leading industry executives and moderates prestigious events. Aidan also oversees the Global Generics & Biosimilars Awards. Aidan speaks fluent German and has a particular affection for maps.
Advertisement
Set Alert for Articles By Aidan Fry

Latest From Aidan Fry

Large Iranian Study Proves The Potential Of Polypill Concept

Data presented in The Lancet medical journal suggests a polypill fixed-dose combination of aspirin, atorvastatin and hydrochlorothiazide with either enalapril or valsartan could reduce the risk of cardiovascular events significantly. 

Value-Added Medicines Cardiovascular

Germany Remains In The Dark On UPC Implementation

With a constitutional challenge still pending in Germany, and lingering uncertainties over Brexit, Germany's federal government appears to have little idea when a planned European Unified Patent Court could come into effect.

Intellectual Property Europe

People Round-Up: All Change At UK Agencies As Brexit Looms

The head of the UK’s health technology assessment body NICE is stepping down, while the country’s medicines agency, the MHRA, will have an interim chief in the run-up to the UK’s planned Brexit from the European Union on 31 October.

Appointments Leadership

FDA Must Act To Improve First-Review Cycle Approval Rates

Greater clarity in reviewers’ comments and limiting the effect of originators’ label changes on pending applications would help improve the rate of generic applications approved by the FDA on the first review cycle, a US government report proposes.

Drug Review FDA

Siegfried Prepares To Start API Exports From China To US

With permission to export bulk drugs from China to the US expected soon, Siegfried is also making strides on offering services for filling biological drugs.

Ingredients China

Alvogen Advances Its Branded Offering Via Agreements

By licensing Covis’ Alvesco ciclesonide inhaler in central and eastern Europe, as well as preparing to launch thee Qysmia weight-loss brand for which it just obtained approval in Korea, Alvogen is expanding its portfolio of branded drugs.

Europe South Korea
See All
Advertisement
UsernamePublicRestriction

Register